Hemispherx (HEB) Continuing Higher as Japanese Researchers Call Ampligen(r) 'Most Promising' Candidate for Flu Vaccines
Shares of the momentous Hemispherx BioPharma (AMEX: HEB) are adding another 16% onto recent gains today following news earlier that scientists at the Japanese National Institute of Infectious Diseases called the company's Ampligen(r) "the most promising adjuvant candidate for mucosal vaccines". The opinion was published in Therapeutics and Clinical Risk Management 2009:5 125-132.
Hemispherx shares most recently traded at $2.95 on extremely heavy volume: the stock has traded more than 10 million times, which compares to its average daily volume of just 7 million shares. Notably, the stock has surged 70% in the last 3 trading sessions and more than 500% since late-April, when swine flu fears first began spreading.
While the stock has certainly run quite dramatically over the last month, it is hard to tell how saturated investor interests might be. Consider Tuesday's news that the WHO said the swine flu situation is 'moving closer to Phase 6', the highest level of pandemic alert.
Hemispherx shares most recently traded at $2.95 on extremely heavy volume: the stock has traded more than 10 million times, which compares to its average daily volume of just 7 million shares. Notably, the stock has surged 70% in the last 3 trading sessions and more than 500% since late-April, when swine flu fears first began spreading.
While the stock has certainly run quite dramatically over the last month, it is hard to tell how saturated investor interests might be. Consider Tuesday's news that the WHO said the swine flu situation is 'moving closer to Phase 6', the highest level of pandemic alert.
You May Also Be Interested In
- OmniVision (OVTI) Volatility Up on Move Lower
- Maastricht Treaty to Blame for Crisis in EU...
- Mattress Stocks Zip Higher on Positive Comments (TPX) (SCSS) (ZZ) (MFRM)
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
